biota has a massive pr problem !!, page-10

Note also that BTA *already* has something at least as good as Peramivir, IV Relenza. Peramivir can only be used IV, is still in the clinical trial stage, and is not yet in full production. Also, it appears that Tamiflu resistance is associated with paramivir resistance, but not necessarily Relenza resistance. And Relenza, while not officially approved for IV use yet, is an established drug already in production. So even *without* LANI BTA trumps Biocryst on the fundamentals of its products.